I. OVERVIEW OF PACKULAIN
Polymactin is a class of antibiotics that have been isolated from the polymix sapulsion culture, including polymixin A, B, C, D, E, among others, in which polymactin B and polymactin E (also known as mucculin) are more applied clinically. Polymactactin-like drugs have a strong antibacterial effect, mainly on the cyanobacteria, by combining with phosphorus in the bacterial membrane, undermining the integrity of the membrane and causing significant material leaks within the cell, leading to bacterial deaths.
II. Accommodative certificates for polymixin
(i) Multi-drug-resistant pneumocococcal infections
In the current context of increasing resistance to antibacterial drugs, polyglucin is an important option for the treatment of multi-drug-resistant eclampia infections. For example, infection caused by the non-activation of bacterium and copper-green-false cystasy in Bowman, which is widely drug-resistant. These bacteria are resistant to a variety of commonly used antibiotics (e.g., carbon methacin, capisculin, etc.), which can be used as a last resort. It plays a role in the access of hospitals to severe infections caused by these resistant strains, such as pneumonia, blood flow infections and infections in the urinary system.
(ii) Bacteria (CRE) infection in carbon methacrylate resistance
The emergence of the CRE presents a great challenge to clinical treatment, with multi-mixer bacterial resistance to selected CRE strains. When patients become infected with CRE and experience severe septicaemia, abdominal infections, etc., the combination of mucus and other appropriate antibacterial drugs may be an effective treatment strategy.
III. Case analysis of the treatment of polymixin
(i) Case description
The patient, a 70-year-old male, suffers from fever, cold warfare, urination frequency, urination acuteness and urinary pain as a result of a long stay in hospital and the retention of a catheter. Laboratory tests showed a white cell count increase (18 x 109/L) and calcium reduction (PCT) 2.0ng/mL. The results of urine culture show a cormoxin-resistant cormorex infection, with a variety of commonly used antibiotics, but sensitive to polymix.
(ii) Treatment process
After the initial treatment of the patient was ineffective with a variety of antibiotics, the treatment began with polymixer E. The dosage of polyglucose E is adjusted to the body weight and kidney function of the patient and is administered by intravenous dripping. At the same time, patients are given treatment for their illnesses, including rehydration to maintain water, electrolyte balance and cooling. In the course of treatment, indicators such as kidney function, blood protocol, etc. are closely monitored.
(iii) The effects of treatment
After three days of treatment, the patient’s body temperature began to decrease and the urinary tract irritation was reduced. After 1 week of continued use of polymixer E, the patient’s body temperature has returned to normal and the white cell count has dropped to 10 x 109/L, PCT 0.5g/mL. A review of the urine culture showed a bacterial transfer. After three days of intensive treatment, the patient’s symptoms are completely gone and his condition is stable.
(iv) Case discussion
This case shows the effectiveness of mucus in the treatment of ngland circulatory urinary system infections for carbon cyanol. However, attention needs to be paid to the possible adverse effects of treatment. In this case, although the kidney function was closely monitored during the treatment and the patient did not suffer significant kidney function impairment, it was a major concern in the use of the fungus.
IV. Attention to the use of polymixin
(i) Renal toxicity
The most significant adverse effects of the mucus are renal toxicity, which can be seen in the rise of haemocelline acetic anhydride, protein urine, blood urine, etc. The kidney function must be closely monitored in the use of polymixin, especially in cases where the kidney function itself is incomplete or in old age. If there are signs of kidney damage, the dose may need to be adjusted or suspended.
(ii) Neurotoxicity
Some patients may have neurotoxic effects, such as dizziness, facial numbness, hysteria, etc. When these symptoms occur in patients, there is also a need to assess the continued use of mucus, which could be considered in combination with other medications or adjustment programmes.
(iii) Drug interaction
There may be interactions between polypactin and other drugs. For example, co-location with amino-sugar-type drugs may increase the risk of renal and neurotoxicity. Therefore, there is a need for a careful assessment in the joint use of drugs to avoid the overloading of adverse effects.
V. THE STATUS AND VISION OF PACKULAIN IN CONTITIVE APPLICATIONS
As the problem of bacterial resistance increases, the role of multi-mixers in the treatment of multi-drug-resistant eclampsia infections becomes increasingly important. However, its extensive use is limited by its severe adverse effects. In the future, on the one hand, there is a need for further research on how to optimize the use of microcosms in order to reduce the occurrence of adverse reactions; on the other hand, new antibacterial drugs or joint treatment strategies are needed to better respond to the serious challenge of multi-drug-resistant infections and to improve patient healing and survival rates. At the same time, clinicians, in the use of multi-mixer bacteria, are required to exercise strict control over the proof of adaptation, to evaluate the advantages and disadvantages, and to exercise caution in the use of medicines to ensure the safety and treatment of patients.
